FDA Approves GSK’s Arexvy to Prevent Respiratory Syncytial Virus in Adults Aged 50-59 with Increased Risk

Posted on by admin
1 min read

Arexvy receives expanded indication to include adults aged 59 years and younger to prevent RSV lower respiratory tract disease.

Avatar for admin
admin https://goorre.com

You May Also Like

More From Author

+ There are no comments

Add yours